{"url":"https://lda.senate.gov/api/v1/filings/960b9c65-12e3-4deb-8caa-efd376bdb2a5/","filing_uuid":"960b9c65-12e3-4deb-8caa-efd376bdb2a5","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2025,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/960b9c65-12e3-4deb-8caa-efd376bdb2a5/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jay Engleson","dt_posted":"2025-10-20T14:54:44-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th St NW, Suite 650","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":65191,"url":"https://lda.senate.gov/api/v1/registrants/65191/","house_registrant_id":35579,"name":"VENN STRATEGIES","description":"A political and public affairs consulting firm.","address_1":"750 9th St NW, Suite 650","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JAY ENGLESON","contact_telephone":"+1 301-509-9933","dt_updated":"2026-07-20T11:43:32.403140-04:00"},"client":{"id":210071,"url":"https://lda.senate.gov/api/v1/clients/210071/","client_id":1003910,"name":"UCB, INC.","general_description":"Biopharmaceutical company dealing in severe diseases in immunology and neurology.","client_government_entity":false,"client_self_select":null,"state":"GA","state_display":"Georgia","country":"US","country_display":"United States of America","ppb_state":"GA","ppb_state_display":"Georgia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Policies related to biopharmaceutical access and innovation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64837,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"SPIRA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"International tax, corporate tax rate, and research and development tax issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139436,"prefix":"mr","prefix_display":"MR.","first_name":"JUSTIN","nickname":null,"middle_name":"ROBERT","last_name":"LIVESEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}